Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2024

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS

Schedule of cash, cash equivalents and short-term investments

Cash, cash equivalents and short-term investments for the periods presented consist of the following (in thousands):


	As of
	March 31, 2024		December 31, 2023
Cash	$	5,843	$	8,247
Money market funds		9,767		9,685
US treasury bills		12,906		12,594
Government-sponsored enterprise securities		5,469		11,233
Corporate bonds and commercial paper		15,565		15,174
	$	49,550	$	56,933
Reported as:
Cash and cash equivalents	$	25,574	$	32,786
Short-term investments		23,976		24,147
	$	49,550	$	56,933

Schedule of cash equivalents and short-term investments including securities with unrealized gains and losses

Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):


			Gross		Gross
	Amortized		Unrealized		Unrealized
As of March 31, 2024	Cost		Gains		Losses		Fair Value
US treasury bills	$	12,907	$	—	$	(1)	$	12,906
Government-sponsored enterprise securities		5,468		2		(1)	$	5,469
Corporate bonds and commercial paper		15,570		1		(6)		15,565
Total	$	33,945	$	3	$	(8)	$	33,940


			Gross		Gross
	Amortized		Unrealized		Unrealized
As of December 31, 2023	Cost		Gains		Losses		Fair Value
US treasury bills	$	12,591	$	3	$	—	$	12,594
Government-sponsored enterprise securities		11,230		7		(4)		11,233
Corporate bonds and commercial paper		15,172		5		(3)		15,174
Total	$	38,993	$	15	$	(7)	$	39,001

Schedule of fair value and gross unrealized losses of investments in unrealized loss position

The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):


As of March 31, 2024	Fair Value		Unrealized Losses
US treasury bills	$	11,919	$	(1)
Government-sponsored enterprise securities		3,986		(1)
Corporate bonds and commercial paper		12,085		(6)
Total	$	27,990	$	(8)